Last reviewed · How we verify
ropinirole dosing for up to 28 days
ropinirole dosing for up to 28 days is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | ropinirole dosing for up to 28 days |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropinirole dosing for up to 28 days CI brief — competitive landscape report
- ropinirole dosing for up to 28 days updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about ropinirole dosing for up to 28 days
What is ropinirole dosing for up to 28 days?
ropinirole dosing for up to 28 days is a Small molecule drug developed by GlaxoSmithKline.
Who makes ropinirole dosing for up to 28 days?
ropinirole dosing for up to 28 days is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is ropinirole dosing for up to 28 days in?
ropinirole dosing for up to 28 days is in Phase 1.